[go: up one dir, main page]

EE9800387A - Implantatsiooni tõhustamine pärast in vitro viljastamist - Google Patents

Implantatsiooni tõhustamine pärast in vitro viljastamist

Info

Publication number
EE9800387A
EE9800387A EE9800387A EE9800387A EE9800387A EE 9800387 A EE9800387 A EE 9800387A EE 9800387 A EE9800387 A EE 9800387A EE 9800387 A EE9800387 A EE 9800387A EE 9800387 A EE9800387 A EE 9800387A
Authority
EE
Estonia
Prior art keywords
implantation
improvement
vitro fertilization
fertilization
vitro
Prior art date
Application number
EE9800387A
Other languages
English (en)
Inventor
Chwalsz Krzysztof
E. Garfield Robert
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE9800387A publication Critical patent/EE9800387A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EE9800387A 1996-05-07 1997-05-07 Implantatsiooni tõhustamine pärast in vitro viljastamist EE9800387A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/646,518 US6040340A (en) 1996-05-07 1996-05-07 Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
PCT/EP1997/002371 WO1997041866A1 (en) 1996-05-07 1997-05-07 Improvement of implantation rates after in vitro fertilization

Publications (1)

Publication Number Publication Date
EE9800387A true EE9800387A (et) 1999-04-15

Family

ID=24593350

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800387A EE9800387A (et) 1996-05-07 1997-05-07 Implantatsiooni tõhustamine pärast in vitro viljastamist

Country Status (17)

Country Link
US (1) US6040340A (et)
EP (1) EP0906105A1 (et)
JP (1) JP2000510462A (et)
KR (1) KR20040097370A (et)
CN (2) CN1679939A (et)
AP (1) AP9801384A0 (et)
BG (1) BG62953B1 (et)
BR (1) BR9708980A (et)
CA (1) CA2253751A1 (et)
EA (1) EA199800986A1 (et)
EE (1) EE9800387A (et)
IL (1) IL126755A0 (et)
IS (1) IS4882A (et)
NO (1) NO985204L (et)
PL (1) PL329766A1 (et)
TR (1) TR199802254T2 (et)
WO (1) WO1997041866A1 (et)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175210A4 (en) 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc STRENGTHENING THE BIODAVAILABILITY OF DRUGS IN THE BRAIN
US7629334B1 (en) * 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
YU13902A (sh) * 1999-08-31 2006-01-16 Schering Ag. Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
WO2001041759A1 (en) * 1999-12-10 2001-06-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulation of oocyte activation
ITMI20002117A1 (it) * 2000-09-29 2002-03-29 Ibsa Inst Biochimique Sa Uso di sodio nitroprussiato in ostetricia e ginecologia
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2003099333A1 (en) * 2002-05-23 2003-12-04 Reproductive Health Technologies, Inc. Methods of controlling fertility, cancers and reproductive tract diseases
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
JP2006514100A (ja) * 2002-10-24 2006-04-27 イーノス・ファーマシューティカルス・インコーポレーテッド 徐放性ｌ−アルギニン製剤並びに製造方法および使用方法
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
CA2540202A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
ES2381884T3 (es) 2003-10-24 2012-06-01 Nora Therapeutics, Inc. Composiciones y métodos para un embarazo saludable
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP1550447A1 (en) * 2004-01-02 2005-07-06 Schering Aktiengesellschaft Menstrual cycle control and improvement of conception rates in females
US20050239758A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
EP1765985A4 (en) 2004-05-17 2008-10-15 Gen Hospital Corp METHOD AND COMPOSITIONS FOR PRODUCING GERM CELLS FROM PERIPHERAL BLOOD RECEIVED GLAND LINK STEM CELLS
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
SG194448A1 (en) 2011-04-14 2013-12-30 Gen Hospital Corp Compositions and methods for autologous germline mitochondrial energy transfer
EA201490050A1 (ru) 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
US5595970A (en) * 1993-07-16 1997-01-21 Schering Aktiengesellschaft Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
US5470847A (en) * 1993-12-10 1995-11-28 Board Of Regents, The University Of Texas System Ovulation control by regulating nitric oxide levels with arginine derivatives

Also Published As

Publication number Publication date
TR199802254T2 (xx) 1999-03-22
NO985204D0 (no) 1998-11-06
PL329766A1 (en) 1999-04-12
KR20040097370A (ko) 2004-11-17
NO985204L (no) 1999-01-06
US6040340A (en) 2000-03-21
BR9708980A (pt) 1999-08-03
BG62953B1 (bg) 2000-12-29
CN1679939A (zh) 2005-10-12
CA2253751A1 (en) 1997-11-13
IS4882A (is) 1998-10-29
AP9801384A0 (en) 1998-12-31
BG102881A (en) 1999-06-30
EA199800986A1 (ru) 1999-04-29
CN1315478C (zh) 2007-05-16
JP2000510462A (ja) 2000-08-15
CN1218402A (zh) 1999-06-02
EP0906105A1 (en) 1999-04-07
IL126755A0 (en) 1999-08-17
WO1997041866A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
EE9800387A (et) Implantatsiooni tõhustamine pärast in vitro viljastamist
DE69729137D1 (de) Stent zur Implantation
FR2751867B1 (fr) Prothese collerette
DE59710859D1 (de) Implantat
DE69729021D1 (de) Flächiges Implantat
FI971955A0 (fi) Dopamineeristen solujen indusointi in vitro
DE59712110D1 (de) Stent
DE69715348D1 (de) Hüftgelenkprothese
PT1300174E (pt) ''kit'' de introducao de implante
EE04540B1 (et) Meetod bioloogiliselt sobivate biodegradeeruvate mikroosakeste valmistamiseks ja mikroosakeste kasutamine
DE69716329D1 (de) Knöchelprothese
BR9702400A (pt) Fecho separável
DE59507573D1 (de) Implantat
DE69715264D1 (de) Knochenprothese
DE59704921D1 (de) Brustprothese
DE69716648D1 (de) Stimmprothese
BR9306919A (pt) Implante peniano
EP0797450A4 (en) In vitro t-lymphopoiesis system
FR2749162B1 (fr) Prothese cotyloidienne
ATA163596A (de) Niederdruck-aufkohlungsanlage
FR2757043B1 (fr) Prothese mammaire
FR2725616B1 (fr) Cupule et prothese cotyloidiennes
KR970000015A (ko) 성장식인공수피시술방법
ID19891A (id) Komposisi gangguan peredaran anti-okular
ATA22593A (de) Einrichtung zur in-vitro-fertilisation

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner